Company Orthocell Limited

Equities

OCC

AU000000OCC6

Biotechnology & Medical Research

Business Summary

Sales per Business

Sales per region

Managers

Members of the board

Share class

Shareholders

Company contact information

Sector

Annual profits - Rate of surprise

Sector Bio Therapeutic Drugs

Market Closed - Australian S.E. Other stock markets 05:19:28 29/04/2024 BST			5-day change	1st Jan Change
0.38 ^AUD	+1.33%		-3.80%	-7.32%

04-15	Orthocell Secures AU$3 Million R&D Tax Rebate for Fiscal Year 2023; Shares Rise 3%	MT
04-09	Orthocell Revenue Soars 19% to AU$1.61 Million in Q1	MT

Orthocell Limited is an Australia-based regenerative medicine company. The Company is focused on regenerating mobility for patients by developing products for the repair of a variety of bone and soft tissue injuries. Its portfolio of products includes CelGro, Striate+, Remplir, and SmrtGraft. CelGro is a collagen medical device that facilitates tissue reconstruction and healing in a variety of dental and orthopedic reconstructive applications. CelGro is manufactured using a SMRT manufacturing process to preserve the natural collagen structure. Striate+ is used for dental GBR applications. Remplir is for peripheral nerve reconstruction. SmrtGraft is for tendon repair. Its other major products are autologous cell therapy, which focuses on regenerating damaged tendon and cartilage tissue. It is engaged in the development of its tendon cell therapy in the United States. Its autologous tendon therapy is an advanced injectable cellular therapy for the treatment of chronic tendon injuries.

AUD in Million	2022	Weight	2023	Weight	Delta
Regenerative Medicine 100.0 %	1	100.0 %	2	100.0 %	+31.47%

AUD in Million	2022	Weight	2023	Weight	Delta
Australia 100.0 %	1	100.0 %	2	100.0 %	+31.47%

Managers	Title	Age	Since
Ming Hao Zheng FOU	Founder	-	20/03/06
Paul Anderson FOU	Founder	58	20/03/06
Nicole Telford DFI	Director of Finance/CFO	-	28/02/06
Alex McHenry COO	Chief Operating Officer	-	31/12/15
Tim Kelaher PRN	Corporate Officer/Principal	-	-
Gregor Maier SAM	Sales & Marketing	-	30/11/14
Peter Webse SEC	Corporate Secretary	61	28/02/23

Members of the board	Title	Age	Since
Fiona Melanie Wood BRD	Director/Board Member	-	24/10/23
John van der Wielen CHM	Chairman	-	31/05/23
Ravi Thadhani BRD	Director/Board Member	-	07/03/23
Paul Anderson FOU	Founder	58	20/03/06
Kim Christian Beazley BRD	Director/Board Member	75	01-14

	Vote	Quantity	Free-Float	Total Float
Stock A	0	338,600	0	74.71 %
Stock B	1	199,267,357	148,880,078 ( 74.71 %)
Stock C	0	1,361,230	0

Name	Equities	%	Valuation
Paul Anderson 3.298 %	6,903,805	3.298 %	2 M $
Ming Hao Zheng 3.251 %	6,805,886	3.251 %	2 M $
Qi Xiao Zhou 2.960 %	6,196,817	2.960 %	2 M $
Jia Xun Xu 2.531 %	5,299,107	2.531 %	1 M $
Sandhurst Trustees Ltd. 2.347 %	4,913,939	2.347 %	1 M $
John Scott Leaver 1.879 %	3,934,058	1.879 %	1 M $
Patrick John Mchale 1.747 %	3,657,147	1.747 %	930 524 $
John Clifford Philpott 1.466 %	3,068,351	1.466 %	780 711 $
Sankofa Strategic Equity Fund Ltd. 0.9373 %	1,962,000	0.9373 %	499 211 $
Tony Athas 0.7644 %	1,600,000	0.7644 %	407 104 $

Orthocell Ltd.

Murdoch University 90 South Street

6150, Murdoch

http://orthocell.com

Company calendar

Healthcare

Pharmaceuticals & Medical Research

Biotechnology & Medical Research

Biotechnology & Medical Research

Bio Therapeutic Drugs

	1st Jan change	Capi.
ORTHOCELL LIMITED	-7.32%	51.19M
VERTEX PHARMACEUTICALS INCORPORATED	-2.57%	103B
REGENERON PHARMACEUTICALS, INC.	+1.58%	95.28B
ARGENX SE	+1.46%	22.15B
BIONTECH SE	-15.53%	21.02B
GENMAB A/S	-8.58%	18.15B
WUXI APPTEC CO., LTD.	-38.74%	16.73B
BEIGENE, LTD.	-12.90%	16.05B
NEUROCRINE BIOSCIENCES, INC.	+5.38%	13.68B
SAREPTA THERAPEUTICS, INC.	+33.51%	12.17B

Bio Therapeutic Drugs